Cargando…
A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
Dupilumab, a monoclonal antibody that inhibits both interleukin (IL)-4 and IL-13 signaling, is an effective treatment option in moderate-to-severe atopic dermatitis (AD). Patients with AD are already at increased risk of developing conjunctivitis, and clinical trials and case reports have shown a gr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890653/ https://www.ncbi.nlm.nih.gov/pubmed/31728936 http://dx.doi.org/10.1007/s40268-019-00288-x |